Albert C. Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Albert C. Lin has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Bradley P. Knight
Department of Medicine (Cardiology) Northwestern University Feinberg School of Medicine Chicago Illinois USA
8 shared publications- Alexandru B. Chicos
Division of Cardiology Northwestern University Chicago Illinois USA
6 shared publications Anna Pfenniger
Division of Cardiology Northwestern University Chicago Illinois USA
6 shared publications- Kaustubha D. Patil
Division of Cardiology Northwestern University Chicago Illinois USA
6 shared publications - Nishant Verma
Division of Cardiology Northwestern University Chicago Illinois USA
6 shared publications - Rod Passman
Division of Cardiology, Feinberg School of Medicine, Northwestern University , 676 N St Claire, Suite 600, Chicago, IL 60611
6 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Cardiac Implantable Electronic Device Infection: Nationwide Trends in Extraction Utilization and In‐Hospital Outcomes
Introduction: Contemporary, real‐world adherence to guideline‐directed transvenous cardiac implantable electronic device (CIED) extraction for patients with CIED infections in the US remains incompletely characterized. As such, we sought to evaluate national trends in CIED extraction and identify factors associated with extraction and in‐hospital mortality. Methods: A retrospective analysis of adult hospitalizations with CIED infection using the National Inpatient Sample from 2016 to 2022 was performed. National trends in extraction, factors associated with extraction, and predictors of in‐hospital mortality were evaluated. Multivariable logistic regression and propensity score matching were used to estimate adjusted associations with mortality. Results: Among 47,835 adults hospitalized with a CIED infection, 10,905 (22.8%) underwent extraction. National extraction rates increased modestly from 16.2% in 2016 to 23.8% in 2022 ( p < 0.001) but remained low overall. Unadjusted in‐hospital mortality was lower among patients who underwent extraction compared with those who did not (2.8% vs. 4.4%; p = 0.001). After adjustment, extraction was independently associated with lower mortality (OR 0.59 [95% CI, 0.44–0.80]). Higher mortality was associated with increasing age, greater comorbidity burden, and markers of acute illness severity, including acute kidney injury, cardiogenic shock, and respiratory failure. Among patients who underwent extraction, markers of acute organ failure remained associated with adjusted in‐hospital mortality. Conclusions: In this contemporary, multi‐payor, national cohort of patients with CIED infections, CIED extraction was independently associated with lower in‐hospital mortality, but was significantly underutilized despite guideline recommendations. Mortality among those who underwent extraction was driven primarily by acute illness severity, emphasizing the need for early recognition and timely intervention. System‐level strategies to improve access to extraction may help align real‐world practice with guidelines.
- 10 August 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Open AccessCardiac Implantable Electronic Device Infection: Nationwide Trends in Extraction Utilization and In‐Hospital Outcomes
Introduction: Contemporary, real‐world adherence to guideline‐directed transvenous cardiac implantable electronic device (CIED) extraction for patients with CIED infections in the US remains incompletely characterized. As such, we sought to evaluate national trends in CIED extraction and identify factors associated with extraction and in‐hospital mortality. Methods: A retrospective analysis of adult hospitalizations with CIED infection using the National Inpatient Sample from 2016 to 2022 was performed. National trends in extraction, factors associated with extraction, and predictors of in‐hospital mortality were evaluated. Multivariable logistic regression and propensity score matching were used to estimate adjusted associations with mortality. Results: Among 47,835 adults hospitalized with a CIED infection, 10,905 (22.8%) underwent extraction. National extraction rates increased modestly from 16.2% in 2016 to 23.8% in 2022 ( p < 0.001) but remained low overall. Unadjusted in‐hospital mortality was lower among patients who underwent extraction compared with those who did not (2.8% vs. 4.4%; p = 0.001). After adjustment, extraction was independently associated with lower mortality (OR 0.59 [95% CI, 0.44–0.80]). Higher mortality was associated with increasing age, greater comorbidity burden, and markers of acute illness severity, including acute kidney injury, cardiogenic shock, and respiratory failure. Among patients who underwent extraction, markers of acute organ failure remained associated with adjusted in‐hospital mortality. Conclusions: In this contemporary, multi‐payor, national cohort of patients with CIED infections, CIED extraction was independently associated with lower in‐hospital mortality, but was significantly underutilized despite guideline recommendations. Mortality among those who underwent extraction was driven primarily by acute illness severity, emphasizing the need for early recognition and timely intervention. System‐level strategies to improve access to extraction may help align real‐world practice with guidelines.
- Open Access
- 2 October 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (12) , 3231-3237
An Ex Vivo Evaluation of Air Intrusion Into Pulsed Field Ablation Sheaths During Ablation and Mapping Catheter Insertion
Introduction: Pulsed field ablation (PFA) is the newest ablation technology, and currently, no data exist on the amount of air intrusion into new, large bore PFA sheaths during ablation or mapping catheter insertion. Methods: An ex vivo study was performed using various combinations of commercially available PFA ablation catheters and sheaths. Common mapping catheters and a non‐PFA steerable sheath were also evaluated as a reference. The siphon principle was used to create negative pressure to simulate left atrial pressure during spontaneous inspiration. Ablation and mapping catheters were advanced to the end of the sheaths under negative pressure and then removed. Air was withdrawn from the sheaths and was measured in milliliters (mL). Results: A total of 55 trials were performed. The average volume of air intrusion with all sheath/catheter combinations was 9.6 + 5.2 mL. The 13 Fr (inner diameter) Faradrive sheath (Boston Scientific Inc.) entrained significantly more air (16.5 + 4.1 mL) compared with the 12 Fr FlexCath Contour sheath (Medtronic Inc.) (6.1 + 2.7 mL, p < 0.01), 13 Fr Agilis NxT sheath (Abbott Inc.) (8.7 + 1.8 mL, p < 0.01), and Vizigo sheath (Johnson & Johnson MedTech Inc.) (5.8 + 2.1 mL, p < 0.01), regardless of the catheter used. There was significantly higher volume of air intrusion with the Farawave ablation catheter through the Faradrive sheath (13.6 + 2.0 mL) than through the 13 Fr Agilis (9.4 + 2.1 mL, p = 0.03) or the PulseSelect through FlexCath Contour sheath (4.0 + 2.7 mL, p < 0.01). Mapping catheters entrained significantly more air than ablation catheters in both the Faradrive (18.0 ± 4.1 mL vs. 13.6 ± 4.1 mL, p = 0.04) and the FlexCath Contour (7.1 ± 2.2 mL vs. 4.0 ± 2.7 mL, p = 0.03). Conclusion: Using a model that simulates left atrial PFA in spontaneously breathing patients, a large volume of air intrusion was observed during insertion and removal of ablation and mapping catheters into new, large bore PFA sheaths. New sheath designs are needed to minimize air intrusion during catheter exchanges to avoid air embolism when performing PFA using left atrial delivery sheaths.
- 2 October 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (12) , 3231-3237
Open AccessAn Ex Vivo Evaluation of Air Intrusion Into Pulsed Field Ablation Sheaths During Ablation and Mapping Catheter Insertion
Introduction: Pulsed field ablation (PFA) is the newest ablation technology, and currently, no data exist on the amount of air intrusion into new, large bore PFA sheaths during ablation or mapping catheter insertion. Methods: An ex vivo study was performed using various combinations of commercially available PFA ablation catheters and sheaths. Common mapping catheters and a non‐PFA steerable sheath were also evaluated as a reference. The siphon principle was used to create negative pressure to simulate left atrial pressure during spontaneous inspiration. Ablation and mapping catheters were advanced to the end of the sheaths under negative pressure and then removed. Air was withdrawn from the sheaths and was measured in milliliters (mL). Results: A total of 55 trials were performed. The average volume of air intrusion with all sheath/catheter combinations was 9.6 + 5.2 mL. The 13 Fr (inner diameter) Faradrive sheath (Boston Scientific Inc.) entrained significantly more air (16.5 + 4.1 mL) compared with the 12 Fr FlexCath Contour sheath (Medtronic Inc.) (6.1 + 2.7 mL, p < 0.01), 13 Fr Agilis NxT sheath (Abbott Inc.) (8.7 + 1.8 mL, p < 0.01), and Vizigo sheath (Johnson & Johnson MedTech Inc.) (5.8 + 2.1 mL, p < 0.01), regardless of the catheter used. There was significantly higher volume of air intrusion with the Farawave ablation catheter through the Faradrive sheath (13.6 + 2.0 mL) than through the 13 Fr Agilis (9.4 + 2.1 mL, p = 0.03) or the PulseSelect through FlexCath Contour sheath (4.0 + 2.7 mL, p < 0.01). Mapping catheters entrained significantly more air than ablation catheters in both the Faradrive (18.0 ± 4.1 mL vs. 13.6 ± 4.1 mL, p = 0.04) and the FlexCath Contour (7.1 ± 2.2 mL vs. 4.0 ± 2.7 mL, p = 0.03). Conclusion: Using a model that simulates left atrial PFA in spontaneously breathing patients, a large volume of air intrusion was observed during insertion and removal of ablation and mapping catheters into new, large bore PFA sheaths. New sheath designs are needed to minimize air intrusion during catheter exchanges to avoid air embolism when performing PFA using left atrial delivery sheaths.
- Open Access
- 10 November 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (1) , 168-176
Rates of and Indications for Subcutaneous ICD Extraction: A Multihospital Healthcare System Analysis
Introduction: The subcutaneous implantable cardioverter defibrillator (S‐ICD) is an alternative to a transvenous ICD in patients who meet the criteria for ICD implantation without concurrent need for cardiac pacing. The objective of this study is to examine the rates of and indications for S‐ICD removal and extraction.Methods: A retrospective analysis of all patients who underwent S‐ICD implantation between 2010 and 2022 at a single multihospital healthcare system was performed. The primary endpoint was S‐ICD removal or extraction. Patient and device characteristics were abstracted from the electronic medical record. Univariate and multivariate analyses were completed to determine factors associated with S‐ICD extraction.Results: A total of 372 patients (69.5% male; 48.6 ± 14.4 years old) underwent S‐ICD implantation during the study period. There were 22 (5.9%) patients (81.8% male; 52.1 ± 13.2 years old) who underwent S‐ICD extraction over a median follow‐up period of 4.4 [2.0−6.5] years. The median length of time between implantation and extraction was 39.6 [8.3−64.6] months. The most common indications for S‐ICD extraction were the need for bradycardia pacing (frequency among extractions, 18.2%), infection (22.7%), and inappropriate shocks due to oversensing (22.7%). A smoking history and higher body mass index were independently associated with S‐ICD extraction.Conclusions: The overall rate of S‐ICD extraction over 4.4 [2.0−6.5] years was 5.9%, with the most common indications for extraction being the need for bradycardia pacing, infection, and inappropriate shocks due to oversensing. A smoking history and high body mass index are associated with increased rates of S‐ICD extraction. With appropriate patient selection for the S‐ICD, the need to remove the device after implantation is low.
- 10 November 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (1) , 168-176
Open AccessRates of and Indications for Subcutaneous ICD Extraction: A Multihospital Healthcare System Analysis
Introduction: The subcutaneous implantable cardioverter defibrillator (S‐ICD) is an alternative to a transvenous ICD in patients who meet the criteria for ICD implantation without concurrent need for cardiac pacing. The objective of this study is to examine the rates of and indications for S‐ICD removal and extraction.Methods: A retrospective analysis of all patients who underwent S‐ICD implantation between 2010 and 2022 at a single multihospital healthcare system was performed. The primary endpoint was S‐ICD removal or extraction. Patient and device characteristics were abstracted from the electronic medical record. Univariate and multivariate analyses were completed to determine factors associated with S‐ICD extraction.Results: A total of 372 patients (69.5% male; 48.6 ± 14.4 years old) underwent S‐ICD implantation during the study period. There were 22 (5.9%) patients (81.8% male; 52.1 ± 13.2 years old) who underwent S‐ICD extraction over a median follow‐up period of 4.4 [2.0−6.5] years. The median length of time between implantation and extraction was 39.6 [8.3−64.6] months. The most common indications for S‐ICD extraction were the need for bradycardia pacing (frequency among extractions, 18.2%), infection (22.7%), and inappropriate shocks due to oversensing (22.7%). A smoking history and higher body mass index were independently associated with S‐ICD extraction.Conclusions: The overall rate of S‐ICD extraction over 4.4 [2.0−6.5] years was 5.9%, with the most common indications for extraction being the need for bradycardia pacing, infection, and inappropriate shocks due to oversensing. A smoking history and high body mass index are associated with increased rates of S‐ICD extraction. With appropriate patient selection for the S‐ICD, the need to remove the device after implantation is low.
- Open Access
- 24 August 2024
- Published by Wiley
Rates of and Indications for Subcutaneous ICD Extraction: A Multihospital Healthcare System Analysis
Introduction : The subcutaneous implantable cardioverter defibrillator (S-ICD) is an alternative to a transvenous ICD in patients who meet criteria for ICD implantation without concurrent need for cardiac pacing. The objective of this study is to examine the rates of and indications for S-ICD removal and extraction. Methods : A retrospective analysis of all patients who underwent S-ICD implantation between 2010 and 2022 at a single multihospital healthcare system was performed. The primary endpoint was S-ICD removal or extraction. Patient and device characteristics were abstracted from the electronic medical record. Univariate and multivariate analyses were completed to determine factors associated with S-ICD extraction. Results : A total of 372 patients (69.5% male; 48.6 ± 14.4 years old) underwent S-ICD implantation during the study period. There were 22 (5.9%) patients (81.8% male; 52.1 ± 13.2 years old) who underwent S-ICD extraction over a median follow up period of 4.4 [2.0-6.5] years. The median length of time between implantation and extraction was 39.6 [8.3-64.6] months. The most common indications for S-ICD extraction were need for bradycardia pacing (incidence, 1.08%), infection (1.34%), and inappropriate shocks due to oversensing (1.34%). A smoking history and higher body mass index were independently associated with S-ICD extraction. Conclusions : The overall rate of S-ICD extraction over 4.4 [2.0-6.5] years was 5.9%, with the most common indications for extraction being need for bradycardia pacing, infection, and inappropriate shocks due to oversensing. A smoking history and high body mass index are associated with increased rates of S-ICD extraction. With appropriate patient selection for the S-ICD, the need to remove the device after implantation is low.
- 24 August 2024
- Published by Wiley
Open AccessRates of and Indications for Subcutaneous ICD Extraction: A Multihospital Healthcare System Analysis
Introduction : The subcutaneous implantable cardioverter defibrillator (S-ICD) is an alternative to a transvenous ICD in patients who meet criteria for ICD implantation without concurrent need for cardiac pacing. The objective of this study is to examine the rates of and indications for S-ICD removal and extraction. Methods : A retrospective analysis of all patients who underwent S-ICD implantation between 2010 and 2022 at a single multihospital healthcare system was performed. The primary endpoint was S-ICD removal or extraction. Patient and device characteristics were abstracted from the electronic medical record. Univariate and multivariate analyses were completed to determine factors associated with S-ICD extraction. Results : A total of 372 patients (69.5% male; 48.6 ± 14.4 years old) underwent S-ICD implantation during the study period. There were 22 (5.9%) patients (81.8% male; 52.1 ± 13.2 years old) who underwent S-ICD extraction over a median follow up period of 4.4 [2.0-6.5] years. The median length of time between implantation and extraction was 39.6 [8.3-64.6] months. The most common indications for S-ICD extraction were need for bradycardia pacing (incidence, 1.08%), infection (1.34%), and inappropriate shocks due to oversensing (1.34%). A smoking history and higher body mass index were independently associated with S-ICD extraction. Conclusions : The overall rate of S-ICD extraction over 4.4 [2.0-6.5] years was 5.9%, with the most common indications for extraction being need for bradycardia pacing, infection, and inappropriate shocks due to oversensing. A smoking history and high body mass index are associated with increased rates of S-ICD extraction. With appropriate patient selection for the S-ICD, the need to remove the device after implantation is low.
- Open Access
- 4 July 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 35 (9) , 1779-1785
Association between high‐density mapping of atypical atrial flutter, clinical outcomes and healthcare utilization
Background: Success of atypical atrial flutter (AAFL) ablation has historically been limited by difficulty mapping the complex re‐entrant circuits involved. While high‐density (HD) mapping has become commonplace in clinical practice, there are limited data on outcomes of HD versus non‐HD mapping for AAFL ablation.Objective: To compare clinical outcomes and healthcare utilization using HD mapping versus non‐HD mapping for AAFL ablation.Methods: Retrospective analysis of all AAFL procedures between 2005 and 2022 at an academic medical center was conducted. Procedures utilizing a 16‐electrode HD Grid catheter and Precision mapping system were compared to procedures using prior generation 10–20 electrode spiral catheters and the Velocity system (Abbott, IL). Cox regression models and Poisson regression models were utilized to examine procedural and healthcare utilization outcomes. Models were adjusted for left ventricular ejection fraction, CHA2DS2‐VASc, and history of prior ablation.Results: There were 108 patients (62% HD mapping) included in the analysis. Baseline clinical characteristics were similar between groups. Use of HD mapping was associated with a higher rate of AAFL circuit delineation (92.5% vs. 76%; p = .014) and a greater adjusted procedure success rate, defined as non‐inducibility at procedure end, (aRR (95% CI) 1.26 (1.02–1.55) p = .035) than non‐HD mapping. HD mapping was also associated with a lower rate of ED visits (aIRR (95% CI) 0.32 (0.14–0.71); p = .007) and hospitalizations (aIRR (95% CI) 0.32 (0.14–0.68); p = .004) for AF/AFL/HF through 1 year. While there was a lower rate of recurrent AFL through 1 year among HD mapping cases (aHR (95% CI) 0.60 (0.31–1.16) p = .13), statistical significance was not met likely due to the low sample size and higher rate of ambulatory rhythm monitoring in the HD group (61% vs. 39%, p = .025).Conclusion: Compared to non‐HD mapping, AAFL ablation with HD mapping is associated with improvements in the ability to define the AAFL circuit, greater procedural success, and a reduction in the number of ED visits and hospitalization for AF/AFL/HF.
- 4 July 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 35 (9) , 1779-1785
Open AccessAssociation between high‐density mapping of atypical atrial flutter, clinical outcomes and healthcare utilization
Background: Success of atypical atrial flutter (AAFL) ablation has historically been limited by difficulty mapping the complex re‐entrant circuits involved. While high‐density (HD) mapping has become commonplace in clinical practice, there are limited data on outcomes of HD versus non‐HD mapping for AAFL ablation.Objective: To compare clinical outcomes and healthcare utilization using HD mapping versus non‐HD mapping for AAFL ablation.Methods: Retrospective analysis of all AAFL procedures between 2005 and 2022 at an academic medical center was conducted. Procedures utilizing a 16‐electrode HD Grid catheter and Precision mapping system were compared to procedures using prior generation 10–20 electrode spiral catheters and the Velocity system (Abbott, IL). Cox regression models and Poisson regression models were utilized to examine procedural and healthcare utilization outcomes. Models were adjusted for left ventricular ejection fraction, CHA2DS2‐VASc, and history of prior ablation.Results: There were 108 patients (62% HD mapping) included in the analysis. Baseline clinical characteristics were similar between groups. Use of HD mapping was associated with a higher rate of AAFL circuit delineation (92.5% vs. 76%; p = .014) and a greater adjusted procedure success rate, defined as non‐inducibility at procedure end, (aRR (95% CI) 1.26 (1.02–1.55) p = .035) than non‐HD mapping. HD mapping was also associated with a lower rate of ED visits (aIRR (95% CI) 0.32 (0.14–0.71); p = .007) and hospitalizations (aIRR (95% CI) 0.32 (0.14–0.68); p = .004) for AF/AFL/HF through 1 year. While there was a lower rate of recurrent AFL through 1 year among HD mapping cases (aHR (95% CI) 0.60 (0.31–1.16) p = .13), statistical significance was not met likely due to the low sample size and higher rate of ambulatory rhythm monitoring in the HD group (61% vs. 39%, p = .025).Conclusion: Compared to non‐HD mapping, AAFL ablation with HD mapping is associated with improvements in the ability to define the AAFL circuit, greater procedural success, and a reduction in the number of ED visits and hospitalization for AF/AFL/HF.
- 26 May 2023
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (6) , 1499-1501
Early and late Watchman device migration and embolization: Insights from the NCDR LAAO registry
- 26 May 2023
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (6) , 1499-1501
Early and late Watchman device migration and embolization: Insights from the NCDR LAAO registry
- Open Access
- 21 September 2022
- Published by Wiley
Implementation of an Intravenous Sotalol Initiation Protocol: Implications for Feasibility, Safety, and Length of Stay
Introduction Oral sotalol initiation requires a multiple-day, inpatient admission to monitor for QT prolongation during loading. A one-day intravenous (IV) sotalol loading protocol was approved by the FDA in March 2020, but limited data on clinical use and administration currently exists. This study describes implementation of an IV sotalol protocol within an integrated health system, provides initial efficacy and safety outcomes, and examines length of stay compared to oral sotalol initiation. Methods IV sotalol was administered according to a pre-specified initiation protocol to adult patients with refractory atrial or ventricular arrhythmias. Baseline characteristics, safety and feasibility outcomes, and length of stay (LOS) were compared to patients receiving oral sotalol over a similar time period. Results From January 2021 to June 2022, a total of 29 patients (average age 66.0 ± 8.6 years, 27.6% women) underwent IV sotalol load and 20 patients (average age 60.4 ± 13.9 years, 65.0% women) underwent PO sotalol load. The load was successfully completed in 22/29 (75.9%) patients receiving IV sotalol and 20/20 (100%) of patients receiving oral sotalol, although 7/20 of the oral sotalol patients (35.0%) required dose reduction. Adverse events interrupting IV sotalol infusion included bradycardia (7 patients, 24.1%) and QT prolongation (3 patients, 10.3%). No patients receiving IV or oral sotalol developed sustained ventricular arrhythmias prior to discharge. LOS for patients completing IV load was 2.6 days shorter (mean 1.0 vs 3.6, p < 0.001) compared to LOS with oral load. Conclusion Intravenous sotalol loading has a safety profile that is similar to oral sotalol. It significantly shortens hospital LOS, potentially leading to large cost savings.
- 21 September 2022
- Published by Wiley
Open AccessImplementation of an Intravenous Sotalol Initiation Protocol: Implications for Feasibility, Safety, and Length of Stay
Introduction Oral sotalol initiation requires a multiple-day, inpatient admission to monitor for QT prolongation during loading. A one-day intravenous (IV) sotalol loading protocol was approved by the FDA in March 2020, but limited data on clinical use and administration currently exists. This study describes implementation of an IV sotalol protocol within an integrated health system, provides initial efficacy and safety outcomes, and examines length of stay compared to oral sotalol initiation. Methods IV sotalol was administered according to a pre-specified initiation protocol to adult patients with refractory atrial or ventricular arrhythmias. Baseline characteristics, safety and feasibility outcomes, and length of stay (LOS) were compared to patients receiving oral sotalol over a similar time period. Results From January 2021 to June 2022, a total of 29 patients (average age 66.0 ± 8.6 years, 27.6% women) underwent IV sotalol load and 20 patients (average age 60.4 ± 13.9 years, 65.0% women) underwent PO sotalol load. The load was successfully completed in 22/29 (75.9%) patients receiving IV sotalol and 20/20 (100%) of patients receiving oral sotalol, although 7/20 of the oral sotalol patients (35.0%) required dose reduction. Adverse events interrupting IV sotalol infusion included bradycardia (7 patients, 24.1%) and QT prolongation (3 patients, 10.3%). No patients receiving IV or oral sotalol developed sustained ventricular arrhythmias prior to discharge. LOS for patients completing IV load was 2.6 days shorter (mean 1.0 vs 3.6, p < 0.001) compared to LOS with oral load. Conclusion Intravenous sotalol loading has a safety profile that is similar to oral sotalol. It significantly shortens hospital LOS, potentially leading to large cost savings.
- Open Access
- 25 September 2021
- Published by Wiley
First-in-Human Use of a Novel 4D Intracardiac Echocardiography Catheter To Guide Interventional Electrophysiology Procedures
Introduction: Standard two-dimensional (2D), phased-array intracardiac echocardiography (ICE) is routinely used to guide interventional electrophysiology (EP) procedures. A novel four-dimensional (4D) ICE catheter (VeriSight Pro®, Philips, Andover, MA) can obtain 2D and three-dimensional (3D) volumetric images and cine-videos in real time (4D). The purpose of this study was to determine the early feasibility and safety of this 4D ICE catheter during EP procedures. Methods: The 4D ICE catheter was placed from the femoral vein in ten patients into various cardiac chambers to guide EP procedures requiring transseptal catheterization, including ablation for atrial fibrillation and left atrial appendage closure. 2D- and 3D- ICE images were acquired in real time by the electrophysiologist. A dedicated imaging expert performed digital steering to optimize and post-process 4D images. Results: Eight patients underwent pulmonary vein isolation (cryoballoon in 7 patients, pulsed field ablation in 1, additional radiofrequency left atrial ablation in 1). Two patients underwent left atrial appendage closure. High quality images of cardiac structures, transseptal catheterization equipment, guide sheaths, ablation tools, and closure devices were acquired with the ICE catheter tip positioned in the right atrium, left atrium, pulmonary vein, coronary sinus, right ventricle, and pulmonary artery. There were no complications. Conclusion: This is the first-in-human experience of a novel deflectable 4D ICE catheter used to guide EP procedures. 4D ICE imaging in safe and allows for acquisition of high-quality 2D and 3D images in real-time. Further use of 4D ICE will be needed to determine its added value for each EP procedure type.
- 25 September 2021
- Published by Wiley
Open AccessFirst-in-Human Use of a Novel 4D Intracardiac Echocardiography Catheter To Guide Interventional Electrophysiology Procedures
Introduction: Standard two-dimensional (2D), phased-array intracardiac echocardiography (ICE) is routinely used to guide interventional electrophysiology (EP) procedures. A novel four-dimensional (4D) ICE catheter (VeriSight Pro®, Philips, Andover, MA) can obtain 2D and three-dimensional (3D) volumetric images and cine-videos in real time (4D). The purpose of this study was to determine the early feasibility and safety of this 4D ICE catheter during EP procedures. Methods: The 4D ICE catheter was placed from the femoral vein in ten patients into various cardiac chambers to guide EP procedures requiring transseptal catheterization, including ablation for atrial fibrillation and left atrial appendage closure. 2D- and 3D- ICE images were acquired in real time by the electrophysiologist. A dedicated imaging expert performed digital steering to optimize and post-process 4D images. Results: Eight patients underwent pulmonary vein isolation (cryoballoon in 7 patients, pulsed field ablation in 1, additional radiofrequency left atrial ablation in 1). Two patients underwent left atrial appendage closure. High quality images of cardiac structures, transseptal catheterization equipment, guide sheaths, ablation tools, and closure devices were acquired with the ICE catheter tip positioned in the right atrium, left atrium, pulmonary vein, coronary sinus, right ventricle, and pulmonary artery. There were no complications. Conclusion: This is the first-in-human experience of a novel deflectable 4D ICE catheter used to guide EP procedures. 4D ICE imaging in safe and allows for acquisition of high-quality 2D and 3D images in real-time. Further use of 4D ICE will be needed to determine its added value for each EP procedure type.
- 29 May 2018
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 41 (8) , 920-926
Long‐term electrical performance of Attain Performa quadripolar left ventricular leads with all steroid‐eluting electrodes: Results from a large worldwide clinical trial
Background: Steroid‐eluting (SE) electrodes suppress local inflammation and lower pacing capture thresholds (PCT); however, their effectiveness on quadripolar left ventricular (LV) leads in the cardiac vein is not fully studied. We evaluated the effectiveness of SE on all four LV pacing electrodes in human subjects enrolled in the Medtronic Attain® Performa™ quadripolar LV lead study.Methods: A total of 1,097 subjects were included in this evaluation. At each follow‐up visit (1, 3, 6, and 12 months), LV PCT and pacing impedance were measured using either manual or automated testing methods. Summary statistics for PCT and impedance values were obtained for implant and each scheduled follow‐up visit for all lead models.Results: Average extended bipolar (LV electrode to right ventricular Coil) PCTs for the four LV SE pacing electrodes (LV1, LV2, LV3, and LV4) on the three shapes of the quadripolar LV leads were 1.06 ± 0.97 V, 1.38 ± 1.26 V, 1.51 ± 1.33 V, and 2.25 ± 1.63 V, respectively, at 0.5‐ms pulse width. PCTs remained low and stable throughout the 12‐month follow‐up period.Conclusion: This clinical trial demonstrated that SE on all LV pacing electrodes is associated with low and stable PCTs for all quadripolar LV lead electrodes, resulting in multiple viable vectors for LV pacing. The large number of available vectors facilitates basal pacing, avoidance of PNS, and potentially prolongs generator longevity due to lower PCTs.
- 29 May 2018
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 41 (8) , 920-926
Long‐term electrical performance of Attain Performa quadripolar left ventricular leads with all steroid‐eluting electrodes: Results from a large worldwide clinical trial
Background: Steroid‐eluting (SE) electrodes suppress local inflammation and lower pacing capture thresholds (PCT); however, their effectiveness on quadripolar left ventricular (LV) leads in the cardiac vein is not fully studied. We evaluated the effectiveness of SE on all four LV pacing electrodes in human subjects enrolled in the Medtronic Attain® Performa™ quadripolar LV lead study.Methods: A total of 1,097 subjects were included in this evaluation. At each follow‐up visit (1, 3, 6, and 12 months), LV PCT and pacing impedance were measured using either manual or automated testing methods. Summary statistics for PCT and impedance values were obtained for implant and each scheduled follow‐up visit for all lead models.Results: Average extended bipolar (LV electrode to right ventricular Coil) PCTs for the four LV SE pacing electrodes (LV1, LV2, LV3, and LV4) on the three shapes of the quadripolar LV leads were 1.06 ± 0.97 V, 1.38 ± 1.26 V, 1.51 ± 1.33 V, and 2.25 ± 1.63 V, respectively, at 0.5‐ms pulse width. PCTs remained low and stable throughout the 12‐month follow‐up period.Conclusion: This clinical trial demonstrated that SE on all LV pacing electrodes is associated with low and stable PCTs for all quadripolar LV lead electrodes, resulting in multiple viable vectors for LV pacing. The large number of available vectors facilitates basal pacing, avoidance of PNS, and potentially prolongs generator longevity due to lower PCTs.
- 6 March 2018
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 20 (3) , 24
What Is the Role of Left Atrial Appendage Closure in the Rhythm Control of Atrial Fibrillation?
Interventional catheter ablation approaches to the rhythm control of atrial fibrillation (AF) have advanced significantly in the past decade. The foundation of the catheter ablation in AF is electrical isolation of the pulmonary veins (PVI). However, PVI only in more advanced stages of AF (persistent AF) has only modest to poor success rates prompting a search for alternative and adjunctive procedures to improve the outcomes of ablation in persistent AF. The left atrial appendage (LAA) is well understood to be a primary source of emboli in AF but less well known be a trigger or driver for AF. Therefore, LAA exclusion is an attractive target to potentially improve AF ablation outcomes in more advanced stages of AF and possibly as an alternative to chronic oral anticoagulation in the prevention of stroke and systemic embolism in AF. However, the precise role of LAA closure in the interventional approach to AF is still to be elucidated with ongoing clinical investigations.
- 6 March 2018
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 20 (3) , 24
What Is the Role of Left Atrial Appendage Closure in the Rhythm Control of Atrial Fibrillation?
Interventional catheter ablation approaches to the rhythm control of atrial fibrillation (AF) have advanced significantly in the past decade. The foundation of the catheter ablation in AF is electrical isolation of the pulmonary veins (PVI). However, PVI only in more advanced stages of AF (persistent AF) has only modest to poor success rates prompting a search for alternative and adjunctive procedures to improve the outcomes of ablation in persistent AF. The left atrial appendage (LAA) is well understood to be a primary source of emboli in AF but less well known be a trigger or driver for AF. Therefore, LAA exclusion is an attractive target to potentially improve AF ablation outcomes in more advanced stages of AF and possibly as an alternative to chronic oral anticoagulation in the prevention of stroke and systemic embolism in AF. However, the precise role of LAA closure in the interventional approach to AF is still to be elucidated with ongoing clinical investigations.